A selenium species in cerebrospinal fluid predicts conversion to Alzheimer’s dementia in persons with mild cognitive impairment

Abstract

BackgroundLittle is known about factors influencing progression from mild cognitive impairment to Alzheimer’s dementia. A potential role of environmental chemicals and specifically of selenium, a trace element of nutritional and toxicological relevance, has been suggested. Epidemiologic studies of selenium are lacking, however, with the exception of a recent randomized trial based on an organic selenium form.MethodsWe determined concentrations of selenium species in cerebrospinal fluid sampled at diagnosis in 56 participants with mild cognitive impairment of nonvascular origin. We then investigated the relation of these concentrations to subsequent conversion from mild cognitive impairment to Alzheimer’s dementia.ResultsTwenty-one out of the 56 subjects developed Alzheimer’s dementia during a median follow-up of 42 months; four subjects developed frontotemporal dementia and two patients Lewy body dementia. In a Cox proportional hazards model adjusting for age, sex, duration of sample storage, and education, an inorganic selenium form, selenate, showed a strong association with Alzheimer’s dementia risk, with an adjusted hazard ratio of 3.1 (95% confidence interval 1.0–9.5) in subjects having a cerebrospinal fluid content above the median level, compared with those with lower concentration. The hazard ratio of Alzheimer’s dementia showed little departure from unity for all other inorganic and organic selenium species. These associations were similar in analyses that measured exposure on a continuous scale, and also after excluding individuals who converted to Alzheimer’s dementia at the beginning of the follow-up.ConclusionsThese results indicate that higher amounts of a potentially toxic inorganic selenium form in cerebrospinal fluid may predict conversion from mild cognitive impairment to Alzheimer’s dementia.Electronic supplementary materialThe online version of this article (doi:10.1186/s13195-017-0323-1) contains supplementary material, which is available to authorized users.

Dietary Estimated Intake of Trace Elements: Risk Assessment in an Italian Population

“…We did not assess the bioavailability of trace elements after food ingestion by determining biological indicators of exposure, although previous studies suggested that only a fraction of total element intake is absorbed, especially in the presence of malabsorption disease (Reilly 2002). In addition, we did not carry out any speciation analysis for the selected elements, in spite of the increasing evidence of the importance of speciation analysis in the exposure assessment of trace elements possibly characterized by either toxicological and nutritional properties/features (Michalke et al 2009(Michalke et al , 2018Ruzik 2012;Vinceti et al 2017). Secondly, we did not differentiate between local and imported samples, hampering the ability to assess such a difference due to geographic origin of products.…”

Comparison of Methodologies to Estimate Dietary Cadmium Intake in an Italian Population

“…This was complemented by our measurement of cadmium in foods commonly consumed by the study population [22]. Our study additionally benefitted from the recruitment of a representative sample of residents from the Modena municipality [8,54]. The characteristics of our study population are similar to those of the overall Italian and regional population [55,56], strengthening the external validity of our results.…”

Selenium, selenoprotein P, and Alzheimer's disease: is there a link?

“…A further cohort study including ALS patients with diseaseassociated mutations (C9ORF72, SOD1, FUS, TARDBP, ATXN2, and TUBA4A) has reported elevated levels of inorganic Se (selenite and selenate), GPX and SELENOP in a patient with the tubulin-related TUBA4A mutation, whereas in the remaining ALS individuals, elevated selenomethionine was observed [36]. Finally, in a recently published study, the increased risk (adjusted hazard ratio of 3.1, 95% confidence interval 1.0-9.5) of developing AD later in life was observed in MCI patients with increased concentration of the potentially toxic inorganic selenium species, selenate, Se(VI), in CSF [150]. The study was conducted in 56 MCI patients; the development of AD was monitored after a median follow-up of 42 months.…”